Summary
-
Xeris Biopharmaceuticals has shown strong technical buy signals, with a 30.03% gain since the Trend Seeker buy signal on 1/28.
The Barchart Brief: Your FREE insider update on the biggest news stories and investing trends, delivered midday The company offers innovative therapies like Gvoke, Keveyis, and Recorlev, and is developing XP-8121 and XeriSol/XeriJect technologies.
Barchart indicators show 100% technical buy signals, a 95.32% gain in the last year, and a Trend Seeker buy signal.
Analysts are bullish with 4 strong buys, 1 buy, and 1 hold, despite MorningStar's view of the stock being 12% overvalued.
The Chart of the Day belongs to the biopharma company Xeris Biopharmaceuticals (XERS) . I found the stock by using Barchart's powerful screening functions to find stocks with the highest technical buy signals, highest Weighted Alpha, superior current momentum and having a Trend Seeker buy signal then used the Flipchart feature to review the charts for consistent price appreciation. Since the Trend Seeker signaled a buy on 1/28 the stock gained 30.03%.
XERS Price vs Daily Moving Averages:
XERS (Barchart)
Xeris Biopharma Holdings, Inc., a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome. It is also developing XP-8121, a once-weekly subcutaneous injection of levothyroxine that is in phase I clinical trial for the treatment of hypothyroidism; and non-aqueous XeriSol and XeriJect technologies for various therapies. The company was incorporated in 2005 and is headquartered in Chicago, Illinois.
Barchart's Opinion Trading systems are listed below. Please note that the Barchart Opinion indicators are updated live during the session every 20 minutes and can therefore change during the day as the market fluctuates. The indicator numbers shown below therefore may not match what you see live on the Barchart.com website when you read this report.
Barchart Technical Indicators:
- 100% technical buy signals
- 129.61+ Weighted Alpha
- 95.32% gain in the last year
- 2.32 - 60 month Beta
- Trend Seeker buy signal
- Above its 20, 50 and 100 day moving averages
- 9 new highs and up 28.57% in the last month
- Relative Strength Index 77.15%
- Technical support level at $4.06
- Recently traded at $4.59 with 50 day moving average of $3.60
Fundamental Factors:
- Market Cap $632 million
- Revenue expected to grow 28.23% this year and another 20.80% next year
- Earnings estimated to increase 92.09% this year and increase again an additional 260.00% next year
Analysts and Investor Sentiment -- I don't buy stocks because everyone else is buying but I do realize that if major firms and investors are dumping a stock it's hard to make money swimming against the tide:
- Wall Street analysts issued 4 strong buy, 1 buy and 1 hold opinion on the stock
- Value Line rates the stock average
- CFRAs MarketScope rates the stock a buy
- MorningStar thinks the stock is 12% over valued
- 5,890 investors monitor the stock on Seeking Alpha where it is rated as the top pharma stock
Additional disclosure: The Barchart Chart of the Day highlights stocks that are experiencing exceptional current price appreciation. They are not intended to be buy recommendations as these stocks are extremely volatile and speculative. Should you decide to add one of these stocks to your investment portfolio it is highly suggested you follow a predetermined diversification and moving stop loss discipline that is consistent with your personal investment risk tolerance and reevaluate your stop losses at least on a weekly basis.
On the date of publication, Jim Van Meerten did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here.
